Phage Therapy Experience at the Eliava Phage Therapy Center: Three Cases of Bacterial Persistence

被引:32
|
作者
Zaldastanishvili, Elisabed [1 ]
Leshkasheli, Lika [1 ]
Dadiani, Mariam [2 ]
Nadareishvili, Lia [2 ]
Askilashvili, Lia [1 ]
Kvatadze, Nino [3 ]
Goderdzishvili, Marina [3 ]
Kutateladze, Mzia [4 ]
Balarjishvili, Nana [1 ]
机构
[1] Eliava Inst Bacteriophages Microbiol & Virol, Lab Mol Biol, Tbilisi 0160, Georgia
[2] Eliava Phage Therapy Ctr EPTC, Tbilisi 0160, Georgia
[3] Eliava Inst Bacteriophages Microbiol & Virol, Lab Gen Microbiol, Tbilisi 0160, Georgia
[4] Eliava Inst Bacteriophages Microbiol & Virol, Tbilisi 0160, Georgia
来源
VIRUSES-BASEL | 2021年 / 13卷 / 10期
关键词
phage therapy; Pseudomonas aeruginosa; Klebsiella pneumoniae;
D O I
10.3390/v13101901
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
In this retrospective descriptive study we focus on cases of three patients who underwent phage therapy procedures at Eliava Phage Therapy Center (EPTC) in Tbilisi, Georgia. Patients with chronic infectious diseases related to Pseudomonas aeruginosa (two patients, lower respiratory tract infection (LRTI)) and Klebsiella pneumoniae (one patient, urinary tract infection (UTI)) are among those very few EPTC patients whose pathogens persisted through phage therapy. By looking at bacterial strains and personalized phages used against them we tried to point towards possible adaptation strategies that are employed by these pathogens. Genome restriction-based Pulsed Field Gel Electrophoresis (PFGE) profiling of strains isolated before and after phage therapy hints towards two strategies of adaptation. In one patient case (Pseudomonas aeruginosa related lung infection) bacterial strains before and after phage therapy were indistinguishable according to their PFGE profiles, but differed in their phage susceptibility properties. On the other hand, in two other patient cases (Pseudomonas aeruginosa related LRTI and Klebsiella pneumoniae related UTI) bacterial adaptation strategy seemed to have resulted in diversification of infecting strains of the same species. With this work we want to attract more attention to phage resistance in general as well as to its role in phage therapy.</p>
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Phage Therapy Pharmacology: Calculating Phage Dosing
    Abedon, Stephen
    ADVANCES IN APPLIED MICROBIOLOGY, VOL 77, 2011, 77 : 1 - 40
  • [42] Phage therapy in IBD
    不详
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2022, 19 (10) : 624 - 624
  • [43] Advocating for phage therapy
    不详
    NATURE MICROBIOLOGY, 2024, 9 (06): : 1397 - 1398
  • [44] The road to phage therapy
    Sankar Adhya
    Carl Merril
    Nature, 2006, 443 (7113) : 754 - 755
  • [45] New phage therapy
    Vandamme, Erick
    CHEMISTRY & INDUSTRY, 2013, 77 (01) : 38 - 41
  • [46] The dawn of phage therapy
    Rehman, Sana
    Ali, Zahid
    Khan, Momna
    Bostan, Nazish
    Naseem, Saadia
    REVIEWS IN MEDICAL VIROLOGY, 2019, 29 (04)
  • [47] Phage therapy for IBD
    Burke, Maria
    CHEMISTRY & INDUSTRY, 2022, 86 (09) : 6 - 6
  • [48] Phage therapy in IBD
    Eleni Kotsiliti
    Nature Reviews Gastroenterology & Hepatology, 2022, 19 : 624 - 624
  • [49] Phage Therapy Pharmacology
    Abedon, Stephen T.
    Thomas-Abedon, Cameron
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2010, 11 (01) : 28 - 47
  • [50] The epic of phage therapy
    Dublanchet, Alain
    Bourne, Shawna
    CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY, 2007, 18 (01): : 15 - 18